Ablynx data on RA candidate boosts partnering
This article was originally published in Scrip
Executive Summary
The awaited 24-week final analysis of the Phase II study of Ablynx's IL-6 receptor inhibitor nanobody ALX-0061, for rheumatoid arthritis has confirmed the interim proof-of-concept data released last October (scripintelligence.com, 4 October 2012). The data will add fuel to Ablynx's partnering discussions for the program.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.